| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Freilich and DeAngelis), Memorial Sloan-Kettering Cancer Center, New York, NY; the Department of Neurology (Dr. Delattre), Hopital de la Salpetriere, Paris, France; and the Department of Neurology (Dr Monjoui), Hopital Louis Pasteur, Colmar, France.
Presented in part at the 47th Annual Meeting of the American Academy of Neurology Seattle, WA, May 1995.
Received March 6, 1995 Accepted in final form June 22, 1995.
Address correspondence and reprint requests to Dr. Lisa M. DeAngelis, Chief, Neurology Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center 1275 York Avenue; New York, NY 10021.
Chemotherapy plus radiation therapy (RT) for primary CNS lymphoma (PCNSL) has significantly improved patient survival over RT alone, but there are late neurologic sequelae of RT, particularly in the elderly.We treated 13 patients over age 50 years (mean age 74 years) with chemotherapy alone as initial treatment for PCNSL. All received methotrexate (MTX) and procarbazine; in addition, five received thiotepa, four vincristine, and four vincristine and cytarabine. Ten achieved a complete response (CR), 2 a partial response (PR), and 1 progressed through treatment. Two patients with ocular lymphoma responded to MTX, procarbazine, and vincristine. Four of six patients who relapsed after achieving a CR or PR were treated with additional chemotherapy or RT, three achieved a CR and one a PR. Five patients remain in CR at 7.5 to 30 months, one is alive at 35 months but with progressive disease, six died of PCNSL at 5 to 30.5 months, and one died in CR of sulfur allergy 2 months after diagnosis. The Karnofsky Performance Status improved in 11 of 13 patients with treatment. Cognitive deficits were present in nine patients at diagnosis and improved in eight of these nine after chemotherapy. Only one patient developed new cognitive deficits, due to progressive tumor and possibly MTX leukoencephalopathy. Chemotherapy alone for PCNSL is effective in the elderly and eliminates the risk of RT-related neurotoxicity. RT can salvage those who relapse after chemotherapy.
NEUROLOGY 1996;46: 435-439
This article has been cited by other articles:
|
|
 |
|
  H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., November 18, 2009; (2009) mdp529v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Ann. Onc., February 1, 2009; 20(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Zhu, E. R. Gerstner, D. A. Engler, M. M. Mrugala, W. Nugent, K. Nierenberg, F. H. Hochberg, R. A. Betensky, and T. T. Batchelor High-dose methotrexate for elderly patients with primary CNS lymphoma Neuro-oncol, January 1, 2009; 11(2): 211 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, N. Yajima, T. Tamura, H. Hondoh, H. Takahashi, et al. Results of Treatment of 112 Cases of Primary CNS Lymphoma Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fliessbach, C. Helmstaedter, H. Urbach, A. Althaus, H. Pels, M. Linnebank, A. Juergens, A. Glasmacher, I. G. Schmidt-Wolf, T. Klockgether, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study Neurology, April 12, 2005; 64(7): 1184 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M.P. Omuro, L. M. DeAngelis, J. Yahalom, and L. E. Abrey Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up Neurology, January 11, 2005; 64(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reni and A. J.M. Ferreri Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas? J. Clin. Oncol., March 15, 2004; 22(6): 1165 - 1167. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Correa, L. M. DeAngelis, W. Shi, H. Thaler, A. Glass, and L. E. Abrey Cognitive functions in survivors of primary central nervous system lymphoma Neurology, February 24, 2004; 62(4): 548 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M.P. Poortmans, H. C. Kluin-Nelemans, H. Haaxma-Reiche, M. Van't Veer, M. Hansen, P. Soubeyran, M. Taphoorn, J. Thomas, M. Van den Bent, M. Fickers, et al. High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962 J. Clin. Oncol., December 15, 2003; 21(24): 4483 - 4488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. DeAngelis Primary Central Nervous System Lymphoma: A Curable Brain Tumor J. Clin. Oncol., December 15, 2003; 21(24): 4471 - 4473. [Full Text] [PDF]
|
|
|
|
|
|
K. Hoang-Xuan, L. Taillandier, O. Chinot, P. Soubeyran, U. Bogdhan, J. Hildebrand, M. Frenay, N. De Beule, J.Y. Delattre, and B. Baron Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group J. Clin. Oncol., July 15, 2003; 21(14): 2726 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Ferreri, L. E. Abrey, J.-Y. Blay, B. Borisch, J. Hochman, E. A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, et al. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002 J. Clin. Oncol., June 15, 2003; 21(12): 2407 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fliessbach, H. Urbach, C. Helmstaedter, H. Pels, A. Glasmacher, J. A. Kraus, T. Klockgether, I. Schmidt-Wolf, and U. Schlegel Cognitive Performance and Magnetic Resonance Imaging Findings After High-Dose Systemic and Intraventricular Chemotherapy for Primary Central Nervous System Lymphoma Arch Neurol, April 1, 2003; 60(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. DeAngelis, W. Seiferheld, S. C. Schold, B. Fisher, and C. J. Schultz Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10 J. Clin. Oncol., December 15, 2002; 20(24): 4643 - 4648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Bessell, A. Lopez-Guillermo, S. Villa, E. Verger, B. Nomdedeu, J. Petit, P. Byrne, E. Montserrat, and F. Graus Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments J. Clin. Oncol., January 1, 2002; 20(1): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Velez, P. Yuan, C. Sung, G. Tansey, G. F. Reed, C.-C. Chan, R. B. Nussenblatt, and M. R. Robinson Pharmacokinetics and Toxicity of Intravitreal Chemotherapy for Primary Intraocular Lymphoma Arch Ophthalmol, October 1, 2001; 119(10): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Soussain, F. Suzan, K. Hoang-Xuan, N. Cassoux, V. Levy, N. Azar, C. Belanger, E. Achour, V. Ribrag, S. Gerber, et al. Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma J. Clin. Oncol., February 1, 2001; 19(3): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Abrey, J. Yahalom, and L. M. DeAngelis Treatment for Primary CNS Lymphoma: The Next Step J. Clin. Oncol., September 17, 2000; 18(17): 3144 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O’Brien, D. Roos, G. Pratt, K. Liew, M. Barton, M. Poulsen, I. Olver, and G. Trotter Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma J. Clin. Oncol., February 1, 2000; 18(3): 519 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ng, M. A. Rosenthal, D. Ashley, and L. Cher High-dose methotrexate for primary CNS lymphoma in the elderly Neuro-oncol, January 1, 2000; 2(1): 40 - 44. [Abstract] [PDF]
|
|
|
|
|
|
B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status Neuro-oncol, July 1, 1999; 1(3): 196 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M DeANGELIS Primary central nervous system lymphoma J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 699 - 701. [Full Text]
|
|
|
|
|
|
B. C. Fishburne, D. J. Wilson, J. T. Rosenbaum, and E. A. Neuwelt Intravitreal Methotrexate as an Adjunctive Treatment of Intraocular Lymphoma Arch Ophthalmol, September 1, 1997; 115(9): 1152 - 1156. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
